Trump negotiating deal with Ozempic maker Novo to sell some weight-loss drugs for $149

The Trump administration is negotiating a deal with weight-loss drugmakers Eli Lilly and Novo Nordisk that would allow the lowest doses of some of their obesity drugs to be sold to consumers at $149 for a month’s supply via TrumpRx, according to people familiar with the matter.

- Liz Essley Whyte & Peter Loftus

The deals would also result in Medicare and Medicaid covering the drugs for weight loss, the people said, which would be a boon to the companies.

The discussions are still ongoing, but if agreements are finalized, President Trump is expected to announce them Thursday morning at the White House, alongside pharmaceutical executives, the people said.

TrumpRx is a website the administration plans to launch in coming months that will make drugs available at prices negotiated by the government.

The agreement would allow Medicaid coverage for the popular but pricey drugs known as GLP-ls, including bestsellers Wegovy and Zepbound, to treat obesity. And it would require Medicare to cover the drugs for obese people who are also at high risk of other health problems, the people familiar with the matter said.

The lowest dose of Novo Nordisk’s Wegovy would be offered through TrumpRx at $149, the people said. The starting dose of Lilly’s Zepbound would be sold for $299, $50 less than the price that the company currently charges patients buying directly through Lilly’s direct-to-consumer website online, according to one of the people.

In addition, Lilly would sell the starting dose of its weight-loss pill, orforglipron, for $149 via TrumpRx if the drug, which is now in testing, is approved by the Food and Drug Administration.